





ثبكة المعلومات الجامعية





جامعة عين شمس

التوثيق الالكتروني والميكروفيلم



نقسم بللله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأفلام قد اعدت دون آية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15-20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of 15-25c and relative humidity 20-40 %



ثبكة المعلومات الجامعية







STUDIES ON SOME ENDOGENOUS DINUCLEOSIDE POLYPHOSPHATES AND THEIR EFFECTS ON THE CARDIOVASCULAR SYSTEM

Thesis.

SUBMITTED FOR THE Ph.D. DEGREE IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY)

By

MAHMOUD MOHAMED KHATTAB

B.Pharm., M.Sc.
ASSISTANT LECTURER, DEPT. OF PHARMACOLOGY & TOXICOLOGY
FACULTY OF PHARMACY
CAIRO UNIVERSITY

UNDER THE SUPERVISION OF

PROF. DR. MOHAMED T. KHAYYAL

Professor of Pharmacology
Dept. of Pharmacology & Toxicology
Faculty of Pharmacy
Cairo University

. 1

PROF. DR. KARL-HEINZ RAHN

Professor & Chairman
Dept. of Internal Medicine D
Faculty of Medicine
Münster University, Germany

PROF. DR. SANAA A. KENAWY

Professor of Pharmacology
Dept. of Pharmacology & Toxicology
Faculty of Pharmacy
Cairo University

Faculty of Pharmacy Cairo University 1997

Approval Sheet

<u>Title of Thesis:</u> STUDIES ON SOME ENDOGENOUS DINUCLEOSIDE POLYPHOSPHATES AND THEIR EFFECTS ON THE CARDIOVASCULAR SYSTEM.

Presented By: MAHMOUD MOHAMED KHATTAB (B.Pharm., M.Sc.)

Assistant Lecturer, Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University

Submitted For: The Ph.D. Degree in Pharmaceutical Sciences (Pharmacology)

Approved By:

1. Prof. Dr. M. T. Khayyal

Professor of Pharmacology, Faculty of Pharmacy, Cairo University

Milianya

2. Prof. Dr. E. Haron

Professor of Pharmacology, Faculty of Medicine, Mansoura University

3. Prof. Dr. M.T. Ghonim

DE KS

Professor of Pharmacology, Faculty of Medicine, Alexandria University

13

(Committee in Charge)

1-0-7

Date: 4/10/1997

Acknowledgements

I am greatly indebted to *Prof. Dr. M.T. Khayyal*, Prof. of Pharmacology, Faculty of Pharmacy, Cairo University. He has strongly motivated me during all phases of this work, helped me keep up my enthusiasm throughout. I have learnt from him basic pharmacological concepts and enjoyed his open-minded scientific discussions.

I am also deeply grateful to *Prof. Dr. K-H. Rahn*, Prof. and Chairman of Internal Medicine Dept., Faculty of Medicine, Münster University, Germany. I feel privileged to have worked under his supervision and enjoyed the family atmosphere in his department for nearly two years. During that time, I can not fail to acknowledge the help and motivation afforded to me by *Prof. Dr. E. Schlatter*, Chairman of Experimental Nephrology Dept., Faculty of Medicine, Münster University, Germany. I am also thankful to all my colleagues and members of the Experimental Nephrology Dept. for providing me with the ideal friendly and scientific atmosphere. My thanks are also to *Dr. H. Hohage*, Münster University, for helping me with the up-dated techniques.

It is a pleasure to express my deep gratitude to *Prof. Dr. Sanaa A. Kenawy*, Prof. of Pharmacology, Faculty of Pharmacy, Cairo University for her continuous encouragement, lending me a lot of support throughout this work.

I would like also to extend my appreciation to *Prof. Dr. W. Zidek*, Prof. of Internal Medicine, Faculty of Medicine, Münster University, for his kind supervision during the in-vitro part of this study as well as to *Dr.H. Schlüter*, Chemist and Biochemist, Faculty of Medicine, Münster University, for his helpful advice.

Last but not least I would like to thank the Egyptian Ministry of Education and the Education and Culture Mission of the Egyptian Embassy in Bonn, Germany for supporting me with the scholarship during my stay in Germany.

CONTENTS

INTRODUCTION

I. Purinergic Mechanisms and Receptors	1
Purine Hypothesis	2
Purinoceptors	5
- P ₁ Purinoceptors (Receptors for Adenosine)	6
- P ₂ Purinoceptors (Receptors for ATP)	10
- P₃ Purinoceptors (Receptors for Adenosine and ATP)	15
- P ₄ Purinoceptors (Receptors in the Nervous System for AP _n A)	17
II. Diadenosine Polyphosphates	18
Storage and Release	19
Catabolism	21
Pharmacological Activity	24
Aim of the Work	34
	•
MATERIALS AND METHODS	36
	30
A to Vites Esperiments on the Install But I and But III I	
A. In-Vitro Experiments on the Isolated Perfused Rat Kidney	
B. In-Vivo Experiments on the Haemodynamics of Anaesthetised Rats	. 40
RESULTS	
RESULIS	
A. In-Vitro Experiments on the Isolated Perfused Rat Kidney	
B. In-Vivo Experiments on the Haemodynamics of Anaesthetised Rats .	59
<u>DISCUSSION</u>	
1. Isolated Perfused Rat Kidney (<i>In-Vitro</i>)	106
2. Haemodynamic Effects of Diadenosine Polyphosphates (In-Vivo)	112
SUMMARY AND CONCLUSIONS	123
REFERENCES	128
	120
ARABIC SUMMARY	

LIST OF TABLES

1. Original Criteria for Distinguishing P ₁ - and P ₂ -Purinoceptors	6
2. Main Characteristics of A_1 - and A_2 - Subclasses of Adenosine	
receptors (P ₁ -Purinoceptors)	7
3. Main Characteristics of the P_{2x} and P_{2y} Subclasses of	
P ₂ -Purinoceptors	10
4. Maximal Effect of Sodium Nitroprusside (SNP), Norepinephrine	
(NE) and Diadenosine Pentaphosphate (AP₅A) on Mean Arterial	
Blood Pressure(MABP), Heart Rate (HR), Renal Blood Flow	
(RBF) and Femoral Blood Flow (FBF)	61
5. Effect of AP₄A on Mean Arterial Blood Pressure (mm Hg)	64
6. Effect of AP₅A on Mean Arterial Blood Pressure (mm Hg)	65
7. Effect of AP₅A on Mean Arterial Blood Pressur (mm Hg)	66
8. Effect of AP ₄ A, AP ₅ A and AP ₆ A on Heart Rate (bpm)	67
9. Effect of AP ₄ A on Renal Bllod Flow (ml/min)	82
10. Effect of AP₅A on Renal Bllod Flow (ml/min)	83
11. Effect of AP ₆ A on Renal Bllod Flow (ml/min)	84
12. Effect of AP ₄ A on Femoral Blood Flow (ml/min)	85
13. Effect of AP₅A on Femoral Blood Flow (ml/min)	86
14. Effect of AP₅A on Femoral Blood Flow (ml/min)	. 87
15. Effect of AP₄A on Renal Vascular Resistance (mm Hg/ml/min)	. 94
16. Effect of AP₅A on Renal Vascular Resistance (mm Hg/ml/min)	95
17. Effect of AP ₆ A on Renal Vascular Resistance (mm Hg/ml/min)	96
18. Effect of AP₄A on Femoral Vascular Resistance (mm Hg/ml/min)	. 98

- 19. Effect of AP₅A on Femoral Vascular Resistance (mm Hg/ml/min).... 99
- 20. Effect of AP₆A on Femoral Vascular Resistance (mm Hg/ml/min) 100

1 .

LIST OF FIGURES

1. How the Small Animal Transonic Flowmeter Works45
2. Vessel Dimensions Independence46
3. Vessel Alignment Insensitivity46
4. Superficial Laser Probe47
5. Dose-Response Effect of AP ₂ A, AP ₃ A, AP ₄ A, AP ₅ A and
AP ₆ A on Changes in Perfusion Pressure of the Isolated
Perfused Rat Kidney
6. Effect of Suramin (500 μ M) on the Change in Perfusion Pressure
Induced by AP₄A, AP₅A and AP₅A in the Isolated Perfused Rat Kidney 51
7. Effect of Alpha,Beta-MeATP (1 μ M) on the Change in Perfusion Pressure
Induced by AP₄A, AP₅A and AP₅A in the Isolated Perfused Rat Kidney 52
8. Effect of Suramin (500 μ M) on the Change in Perfusion Pressure
Induced by AP₂A and AP₃A in the Isolated Perfused Rat Kidney 53
9. Effect of Alpha,Beta-MeATP (1 μ M) on the Change in Perfusion Pressure
Induced by AP₂A and AP₃A in the Isolated Perfused Rat Kidney 54
10. Effect of PPADS (10 μ M) on the Change in Perfusion Pressure
Induced by AP₄A, AP₅A and AP₅A in the Isolated Perfused Rat Kidney 56
11. Effect of 1,3-Dipropyl-8-Cyclopetylxanthine (CPDPX) (10 μM)
on the Change in Perfusion Pressure Induced by AP₄A, AP₅A
and AP₅A in the Isolated Perfused Rat Kidney57
12. Effect of 3,7-Dimethyl-1-Propargylxanthine (DMPX) (10 μM)
on the Change in Perfusion Pressure Induced by AP₄A, AP₅A

and AP₅A in the Isolated Perfused Rat Kidney 58
13. Effect of Saline (0.5 ml) on Heart Rate (HR), Mean Arterial
Blood Pressure (MABP), Renal Blood Flow (RBF) and
Femoral Blood Flow (RBF)60
14. Dose-Response Effect of AP₄A, AP₅A and AP₅A on Heart Rate (HR)
and Mean Arterial Blood Pressure (MABP) 68
15. Effect of AP₄A 0.75 mg/kg on Heart Rate (HR), Mean Arterial Blood
Pressure (MABP), Cardiac Output (CO) and Total Peripheral
Resistance (TPR) 70
16. Effect of AP₄A 0.75 mg/kg on Mean Arterial Blood Pressure
(MABP) and Heart Rate (HR)71
17. Effect of AP₄A 0.75 mg7kg on Cardiac Output (CO) and
Total Peripheral Resistance (TPR)
18. Effect of AP₅A 0.75 mg/kg on Heart Rate (HR), Mean Arterial Blood
Pressure (MABP), Cardiac Output (CO) and Total Peripheral
Resistance (TPR) 74
19. Effect of AP₅A 0.75 mg/kg on Mean Arterial Blood Pressure
(MABP) and Heart Rate (HR) 75
20. Effect of AP₅A 0.75 mg7kg on Cardiac Output (CO) and
Total Peripheral Resistance (TPR)
21. Effect of AP₅A 0.75 mg/kg on Heart Rate (HR), Mean Arterial Blood
Pressure (MABP), Cardiac Output (CO) and Total Peripheral
Resistance (TPR) 78

22. Effect of AP₅A 0.75 mg/kg on Mean Arterial Blood Pressure
(MABP) and Heart Rate (HR) 79
23. Effect of AP ₆ A 0.75 mg7kg on Cardiac Output (CO) and
Total Peripheral Resistance (TPR) 80
24. Effect of AP₄A 0.75 mg/kg on Renal Blood Flow (RBF), Superficial
Renal Microcirculation (SRMC) and Femoral Blood Flow (FBF)
25. Effect of AP₅A 0.75 mg/kg on Renal Blood Flow (RBF), Superficial
Renal Microcirculation (SRMC) and Femoral Blood Flow (FBF) 90
26. Effect of AP₅A 0.75 mg/kg on Renal Blood Flow (RBF), Superficial
Renal Microcirculation (SRMC) and Femoral Blood Flow (FBF) 93
27. Dose-Response Effect of AP₄A, AP₅A and AP₅A on the Maximal
Increase in Renal Vascular Resistance (RVR)
28. Effect of AP₄A 0.75 mg/kg on Femoral and Renal
Vascular Resistance 102
29. Effect of AP₅A 0.75 mg/kg on Femoral and Renal
Vascular Resistance 103
30. Effect of AP₅A 0.75 mg/kg on Femoral and Renal
Vascular Resistance